|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600123880 |
|
最近更新日期: Date of Last Refreshed on: |
2026-04-30 15:30:22 |
|
注册时间: Date of Registration: |
2026-04-30 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
重症急性胰腺炎患者症状群纵向演变及核心症状识别研究 |
|
Public title: |
Longitudinal Evolution of Symptom Clusters and Identification of Core Symptoms in Patients with Severe Acute Pancreatitis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
重症急性胰腺炎患者症状群纵向演变及核心症状识别研究 |
|
Scientific title: |
Longitudinal Evolution of Symptom Clusters and Identification of Core Symptoms in Patients with Severe Acute Pancreatitis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
黄敬英 |
研究负责人: |
黄敬英 |
|
Applicant: |
Jingying Huang |
Study leader: |
Huang Jingying |
|
申请注册联系人电话: Applicant telephone: |
+86 17757173794 |
研究负责人电话: Study leader's telephone: |
+86 577 6684741 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
3407109@zju.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
3407109@zju.edu.cn |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国浙江省杭州市江干区庆春东路3号 |
研究负责人通讯地址: |
中国浙江省杭州市江干区庆春东路3号 |
|
Applicant address: |
3 Qingchun East Road, Jianggan District, Hangzhou, Zhejiang, China |
Study leader's address: |
3 Qingchun East Road, Jianggan District, Hangzhou, Zhejiang, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
浙江大学医学院附属邵逸夫医院 |
||
|
Applicant's institution: |
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||
|
研究负责人所在单位: |
浙江大学医学院附属邵逸夫医院 |
||
|
Affiliation of the Leader: |
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
邵逸夫医院伦审2026研第0338号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
浙江大学医学院附属邵逸夫医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Sir Run Run Shaw Hospital, Zhejiang University School of Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-04-06 00:00:00 |
||
|
伦理委员会联系人: |
杨漾池 |
||
|
Contact Name of the ethic committee: |
Yang Yangchi |
||
|
伦理委员会联系地址: |
中国浙江省杭州市江干区庆春东路3号 |
||
|
Contact Address of the ethic committee: |
3 Qingchun East Road, Jianggan District, Hangzhou, Zhejiang, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 571 86006811 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
yyc261@foxmail.com |
|
研究实施负责(组长)单位: |
浙江大学医学院附属邵逸夫医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国浙江省杭州市江干区庆春东路3号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
3 Qingchun East Road, Jianggan District, Hangzhou, Zhejiang, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Self funded |
||||||||||||||||||||||
|
Target disease: |
Severe Acute Pancreatitis |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
1.明确 SAP 患者症状群轨迹的演变规律:通过前瞻性纵向追踪研究,动态评估 SAP 患者从转入 ICU、普通病房治疗至出院后这一完整康复周期内,生理及心理症状的发生率、严重程度及演变趋势,从宏观维度掌握患者症状负荷的纵向动态轨迹。 2.识别症状间的交互结构与纵向预测效应:运用网络分析,识别出网络中起关键驱动作用的核心症状,同时揭示症状间的纵向交互影响机制,从而确定症状演化的关键靶点。 |
||||||||||||||||||||||
|
Objectives of Study: |
1. Clarify the evolutionary patterns of symptom cluster trajectories in SAP patients: Through a prospective longitudinal study, this research will dynamically evaluate the incidence, severity, and evolutionary trends of physical and psychological symptoms across the entire recovery cycle—spanning from ICU admission and general ward treatment to post-discharge. This approach aims to grasp the longitudinal dynamic trajectory of patients' symptom burden from a macroscopic perspective. 2. Identify the interactive structures and longitudinal predictive effects among symptoms: Utilizing network analysis, this study will identify the core symptoms that exert a key driving role within the network. Concurrently, it will reveal the longitudinal interactive mechanisms among symptoms, thereby determining the crucial targets for symptom evolution. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.≥18周岁。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Aged >= 18 years. 2.Meet the diagnostic criteria for Severe Acute Pancreatitis (SAP) as defined in the Guidelines for Diagnosis and Treatment of Acute Pancreatitis in China (2021): (1) Persistent upper abdominal pain; (2) Serum amylase and/or lipase levels >= 3 times the upper limit of normal; (3) Diagnosis confirmed by abdominal CT or other imaging modalities; (4) Persistent (> 48h) organ failure, defined as a modified Marshall score > 2. A diagnosis of SAP is established if the patient meets at least two of the first three criteria, along with the fourth criterion. 3.Length of stay in the Intensive Care Unit (ICU) > 72 hours. 4.Voluntary participation in this study with a signed informed consent form (ICF). If the subject is unable to read and sign the ICF due to lack of behavioral capacity or other reasons, their legal guardian/authorized representative must act as a proxy for the informed consent process and sign the ICF on their behalf. |
||||||||||||||||||||||
|
排除标准: |
1.患有其他严重疾病者,如心、肝、肺、肾功能不全及恶性肿瘤等; |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Patients with other severe underlying diseases, such as cardiac, hepatic, pulmonary, or renal dysfunction/insufficiency, and malignant tumors. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-05-05 00:00:00至 To 2027-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-05-05 00:00:00 至 To 2027-04-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究计划采用院内线下发放调查问卷的形式进行数据收集。在征得医院及相关科室许可后,严格根据纳排标准筛选研究对象。调查工作均在确保患者意识清楚、生命体征平稳,且经主管医生或责任护士评估病情允许的前提下开展,以最大程度减少患者生理不适或急性应激对调查质量的影响。在取得研究对象知情同意后,调查人员将提供统一规范的指导,解释如何填写调查问卷及注意事项,确保研究对象能够准确如实地完成填写。完成调查后,研究人员将再次审核调查问卷的完整性,并协助患者补全遗漏的部分,以确保数据的完整性和有效,其中超过 20%数据缺失的调查问卷将被视为无效。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection for this study will be conducted through on-site questionnaire distribution within the hospital. Upon obtaining permission from the hospital and relevant departments, study subjects will be strictly screened according to the inclusion and exclusion criteria. Surveys will only be administered under the premise that the patient is conscious with stable vital signs, and after the attending physician or primary nurse has assessed that the patient's condition permits participation. This approach aims to minimize the impact of physical discomfort or acute stress on the quality of the investigation.After obtaining informed consent from the participants, investigators will provide standardized instructions, explaining how to complete the questionnaire and highlighting key precautions to ensure accurate and truthful responses. Upon completion, researchers will review the questionnaires for completeness and assist patients in filling out any missing sections to ensure data integrity and validity. Questionnaires with more than 20% missing data will be considered invalid. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |